This study extends the emerging paradigm of JAK3 activating mutations [5, 7, 41] to CTCL and further implicates SOCS1 in the control of lymphomatous signaling, thus widening the number of potentially actionable targets in affected neoplasms. This evidence concerns the gene JAK3 and neoplasm.